Synthesis and evaluation of tripeptidyl α-ketoamides as human rhinovirus 3C protease inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 20, 2003, Pages 3531-3536

  Chen, Shu Hui ^a   Lamar, Jason ^a   Victor, Frantz ^a   Snyder, Nancy ^a   Johnson, Robert ^a   Heinz, Beverly A ^a   Wakulchik, Mark ^a   Wang, Q May ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA KETOAMIDE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN RHINOVIRUS; PROTEINASE INHIBITION;

HUMAN RHINOVIRUS 14; HUMAN RHINOVIRUS 3; HUMAN RHINOVIRUS SP.; RHINOVIRUS;

EID: 0141627972     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00753-4     Document Type: Article

References (29)

1. Couch, R. B. In Virology; Fields, B. N., Knipe, D. M., Eds.; Raven: New York, 1990.
2. Porter A.G. J. Virol. 67:1993;6917.
3. Matthews D.A., Smith W.A., Ferre R.A., Condon B. Cell. 77:1994;761.
4. HRV substrates:(a) Cordingley M.G., Callahan P.L., Sardana V.V., Garsky V.M., Colonno R.J. J. Biochem. 265:1990;9062 (b) Wang Q.M., Johnson R.B., Cox G.A., Villareal E.C., Loncharich R.J. Anal. Biochem. 252:1997;238.
5. HRV substrates:(a) Cordingley M.G., Callahan P.L., Sardana V.V., Garsky V.M., Colonno R.J. J. Biochem. 265:1990;9062 (b) Wang Q.M., Johnson R.B., Cox G.A., Villareal E.C., Loncharich R.J. Anal. Biochem. 252:1997;238.
6. Recent Reviews: (a) Dragovich P.S. Exp. Opin. Ther. Pat. 11:2001;177 (b) Wang Q.M. Drugs Future. 25:2000;279.
7. Recent Reviews: (a) Dragovich P.S. Exp. Opin. Ther. Pat. 11:2001;177 (b) Wang Q.M. Drugs Future. 25:2000;279.
8. (a) AG-7088: Dragovich P.S., Prins T.J., Zhou R., Webber S.E., Marakovits J.T., Fuhrman S.A., Patick A.K., Matthews D.A., Lee C.A., Ford C.E., Burke B.J., Rejto P.A., Hendrickson T.F., Tuntland T., Brown E.L., Meador J.W. III., Ferre R.A., Harr J.E.V., Kosa M.B., Worland S.T. J. Med. Chem. 42:1999;1213
9. (b) Dragovich P.S., Prins T.J., Zhou R., Fuhrman S.A., Patick A.K., Matthews D.A., Ford C.E., Meador J.W. III, Ferre R.A., Worland S.T. J. Med. Chem. 42:1999;1203.
10. Kong J.S., Venkatraman S., Furness K., Nimkar S., Shepherd T.A., Wang Q.M., Aube J., Hanzlik R.P. J. Med. Chem. 41:1998;2579.
11. (a) Kaldor S.W., Hammond M., Dressman B.A., Labus J.M., Chadwell F.W., Kline A.D., Heinz B.A. Bioorg. Med. Chem. Lett. 5:1995;2021
12. (b) Shepherd T.A., Cox G.A., McKinney E., Tang J., Wakulchik M., Zimmerman R.E., Villarreal E.C. Bioorg. Med. Chem. Lett. 6:1996;2893
13. (c) Webber S.E., Okano K., Little T.L., Reich S.H., Xin Y., Fuhrman S.A., Matthews D.A., Love R.A., Hendrickson T.F., Patick A.K., Meador J.W. III., Ferre R.A., Brown E.L., Ford C.E., Binford S.L., Worland S.T. J. Med. Chem. 41:1998;2786.
14. Dragovich P.S., Zhou R., Webber S.E., Prins T.J., Kwok A.K., Okano K., Fuhrman S.A., Zalman L.S., Maldonado F.C., Brown E.L., Meador J.W., Patick A.K., Ford C.E., Brothers M.A., Binford S.L., Matthews D.A., Ferre R.A., Worland S.T. Bioorg. Med. Chem. Lett. 10:2000;45.
15. Venkatraman S., Kong J., Nimkar S., Wang Q.M., Aube J., Hanzlik R.P. Bioorg. Med. Chem. Lett. 9:1999;577.
16. Kati W.M., Sham H.L., McCall J.O., Montgomery D.A., Wang G.T., Rosenbrook W., Miesbauer L., Buko A., Norbeck D.W. Arch. Biophys. Biochem. 362:1999;363.
17. Xian M., Wang Q.M., Chen X., Wang K., Wang P.G. Bioorg. Med. Chem. Lett. 10:2000;2097.
18. c.f. Monn J.A., Valli M.J. J. Org. Chem. 59:1994;2773. The enatiomerically pure material was obtained via chiral HPLC separation.
19. Barton D.H.R., McCombie S.W. J. Chem. Soc., Perkin Trans. 1. 1975;1574.
20. Carpino L.A., El-Faham A. Tetrahedron. 55:1999;6813.
21. Costa J., Le-Nguyen D., Castro B. Tetrahedron Lett. 31:1990;205.
22. Dess D.B., Martin J.C. J. Org. Chem. 48:1983;4155.
23. (a) Hudlicky M. Org. React. 35:1987;513
24. (b) Leory J., Hebert E., Wakselman C. J. Org. Chem. 44:1979;3406.
25. P1-Nvaline bearing α-hydroxyacid was prepared from Z-Nva(H) via its corresponding cyanohydrin intermediate.
26. i values were calculated according to the following reference: Morrison, J. F. Biochim. Biophys. Acta. 1969, 185, 269 for tight binding inhibitors. The Prism program (GraphPad Software) was used for this procedure.
27. Cell-based antiviral assays were performed using confluent monolayers of HeLa cells infected with either HRV14 or HRV16 under the conditions described in the following reference: J. Med. Chem. 1999, 42, 50.
28. XTT cytotoxicity assay: HeLa cells were cultured under the identical conditions without virus infection but with the test compounds. Also see: Roehm N.W., Rodgers G.H., Hatfield S.M., Glasebrook A.L. J. Immunol. Methods. 142:1991;257.
29. For α-ketoamide based HCV protease inhibitors, see: Babine, R.; Chen, S. H.; Lamar, J.; Snyder, N.; Sun, X.; Tebbe, M.; Victor, F.; Wang, Q. M. ; Yip, Y.; Collado, I.; Garcia-Paredes, C.; Parker, R.; Jin, L.; Guo, D.; Glass, J. PCT Patent WO 0218369 A2, March 7, 2002. Detailed reports describing P1 (Nva) racemization under cell culture media and rat plasma will be published in due time.